Pages that link to "Q60695950"

The following pages link to Myoclonus-dystonia: Clinical and electrophysiologic pattern related to SGCE mutations (Q60695950):

Displaying 32 items.

• Treatment of myoclonus (Q27025673) (← links)
• Distribution and Coexistence of Myoclonus and Dystonia as Clinical Predictors of SGCE Mutation Status: A Pilot Study. (Q27318347) (← links)
• CACNA1B mutation is linked to unique myoclonus-dystonia syndrome (Q28249383) (← links)
• Myoclonus-dystonia syndrome due to tyrosine hydroxylase deficiency (Q30419465) (← links)
• Myoclonic disorders: a practical approach for diagnosis and treatment (Q30476943) (← links)
• High-throughput mutational analysis of TOR1A in primary dystonia (Q33417896) (← links)
• Clinical and neurophysiological improvement of SGCE myoclonus-dystonia with GPi deep brain stimulation (Q33625157) (← links)
• SGCE mutations cause psychiatric disorders: clinical and genetic characterization (Q33738468) (← links)
• Abnormal nuclear envelope in the cerebellar Purkinje cells and impaired motor learning in DYT11 myoclonus-dystonia mouse models (Q34063055) (← links)
• New approaches in dystonia (clinical features, genetic issues and pathophysiology (Q34178139) (← links)
• A patient with genetically confirmed myoclonus-dystonia responded to anticholinergic treatment and improved spontaneously. (Q35675992) (← links)
• Abnormal nuclear envelopes in the striatum and motor deficits in DYT11 myoclonus-dystonia mouse models (Q35688598) (← links)
• SGCE and myoclonus dystonia: motor characteristics, diagnostic criteria and clinical predictors of genotype. (Q35829768) (← links)
• Familial cortical myoclonus with a mutation in NOL3. (Q36200469) (← links)
• Recent advances in the molecular pathogenesis of dystonia-plus syndromes and heredodegenerative dystonias. (Q36634147) (← links)
• Metabolic changes in DYT11 myoclonus-dystonia (Q36659593) (← links)
• A point mutation in ε-sarcoglycan induces inherited myoclonus dystonia syndrome in a Chinese family (Q36781663) (← links)
• Phenotypic insights into ADCY5-associated disease. (Q37106361) (← links)
• Management of patients with myoclonus: available therapies and the need for an evidence-based approach (Q37791719) (← links)
• Myoclonus-dystonia syndrome (Q37865678) (← links)
• Psychiatric disorders, myoclonus dystonia, and the epsilon‐sarcoglycan gene: A systematic review (Q37895597) (← links)
• Treatment for dystonia in childhood (Q37979912) (← links)
• The genetics of dystonia: new twists in an old tale (Q38115272) (← links)
• Myoclonic Disorders (Q52088402) (← links)
• A gain-of-glycosylation mutation associated with myoclonus-dystonia syndrome affects trafficking and processing of mouse ε-sarcoglycan in the late secretory pathway. (Q53413310) (← links)
• Myoclonus-dystonia and epilepsy in a family with a novel epsilon-sarcoglycan mutation. (Q54501751) (← links)
• Myoclonus-dystonia syndrome: case report. (Q55085213) (← links)
• Severity of dystonia is correlated with putaminal gray matter changes in Myoclonus-Dystonia (Q83186332) (← links)
• Prominent Lower-Limb Involvement in a Family with Myoclonus-Dystonia (Q92586785) (← links)
• Gait Impairment in Myoclonus-Dystonia (DYT-SGCE) (Q92628307) (← links)
• Delayed Diagnoses of SGCE Myoclonus-Dystonia (Q98290533) (← links)
• Dissociation in reactive and proactive inhibitory control in Myoclonus dystonia (Q98564852) (← links)